The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death. Sorafenib is approved by the U.S. Food and Drug Administration to be a first-line chemotherapy agent for patients with advanced HCC. A portion of advanced HCC patients can benefit from the treatment with sorafeni...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.696705/full |
| _version_ | 1818656116685406208 |
|---|---|
| author | Xinyao Hu Xinyao Hu Hua Zhu Yang Shen Yang Shen Xiaoyu Zhang Xiaoyu Zhang Xiaoqin He Xiaoqin He Ximing Xu Ximing Xu |
| author_facet | Xinyao Hu Xinyao Hu Hua Zhu Yang Shen Yang Shen Xiaoyu Zhang Xiaoyu Zhang Xiaoqin He Xiaoqin He Ximing Xu Ximing Xu |
| author_sort | Xinyao Hu |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death. Sorafenib is approved by the U.S. Food and Drug Administration to be a first-line chemotherapy agent for patients with advanced HCC. A portion of advanced HCC patients can benefit from the treatment with sorafenib, but many patients ultimately develop sorafenib resistance, leading to a poor prognosis. The molecular mechanisms of sorafenib resistance are sophisticated and indefinite. Notably, non-coding RNAs (ncRNAs), which include long ncRNAs (lncRNAs), microRNAs (miRNAs) and circular RNAs (circRNAs), are critically participated in the occurrence and progression of tumors. Moreover, growing evidence has suggested that ncRNAs are crucial regulators in the development of resistance to sorafenib. Herein, we integrally and systematically summarized the molecular mechanisms and vital role of ncRNAs impact sorafenib resistance of HCC, and ultimately explored the potential clinical administrations of ncRNAs as new prognostic biomarkers and therapeutic targets for HCC. |
| first_indexed | 2024-12-17T03:20:28Z |
| format | Article |
| id | doaj.art-858c53a077c044f38a9d27c56d5d2f13 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-17T03:20:28Z |
| publishDate | 2021-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-858c53a077c044f38a9d27c56d5d2f132022-12-21T22:05:32ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-07-011110.3389/fonc.2021.696705696705The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular CarcinomaXinyao Hu0Xinyao Hu1Hua Zhu2Yang Shen3Yang Shen4Xiaoyu Zhang5Xiaoyu Zhang6Xiaoqin He7Xiaoqin He8Ximing Xu9Ximing Xu10Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, ChinaCancer Center, Renmin Hospital of Wuhan University, Wuhan, ChinaDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, ChinaDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, ChinaCancer Center, Renmin Hospital of Wuhan University, Wuhan, ChinaDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, ChinaCancer Center, Renmin Hospital of Wuhan University, Wuhan, ChinaDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, ChinaCancer Center, Renmin Hospital of Wuhan University, Wuhan, ChinaDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, ChinaCancer Center, Renmin Hospital of Wuhan University, Wuhan, ChinaHepatocellular carcinoma (HCC) is the second most common cause of cancer-related death. Sorafenib is approved by the U.S. Food and Drug Administration to be a first-line chemotherapy agent for patients with advanced HCC. A portion of advanced HCC patients can benefit from the treatment with sorafenib, but many patients ultimately develop sorafenib resistance, leading to a poor prognosis. The molecular mechanisms of sorafenib resistance are sophisticated and indefinite. Notably, non-coding RNAs (ncRNAs), which include long ncRNAs (lncRNAs), microRNAs (miRNAs) and circular RNAs (circRNAs), are critically participated in the occurrence and progression of tumors. Moreover, growing evidence has suggested that ncRNAs are crucial regulators in the development of resistance to sorafenib. Herein, we integrally and systematically summarized the molecular mechanisms and vital role of ncRNAs impact sorafenib resistance of HCC, and ultimately explored the potential clinical administrations of ncRNAs as new prognostic biomarkers and therapeutic targets for HCC.https://www.frontiersin.org/articles/10.3389/fonc.2021.696705/fullhepatocellular carcinomasorafenib resistancemicroRNAlong non-coding RNAcircular RNA |
| spellingShingle | Xinyao Hu Xinyao Hu Hua Zhu Yang Shen Yang Shen Xiaoyu Zhang Xiaoyu Zhang Xiaoqin He Xiaoqin He Ximing Xu Ximing Xu The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma Frontiers in Oncology hepatocellular carcinoma sorafenib resistance microRNA long non-coding RNA circular RNA |
| title | The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma |
| title_full | The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma |
| title_fullStr | The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma |
| title_full_unstemmed | The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma |
| title_short | The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma |
| title_sort | role of non coding rnas in the sorafenib resistance of hepatocellular carcinoma |
| topic | hepatocellular carcinoma sorafenib resistance microRNA long non-coding RNA circular RNA |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.696705/full |
| work_keys_str_mv | AT xinyaohu theroleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma AT xinyaohu theroleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma AT huazhu theroleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma AT yangshen theroleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma AT yangshen theroleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma AT xiaoyuzhang theroleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma AT xiaoyuzhang theroleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma AT xiaoqinhe theroleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma AT xiaoqinhe theroleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma AT ximingxu theroleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma AT ximingxu theroleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma AT xinyaohu roleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma AT xinyaohu roleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma AT huazhu roleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma AT yangshen roleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma AT yangshen roleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma AT xiaoyuzhang roleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma AT xiaoyuzhang roleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma AT xiaoqinhe roleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma AT xiaoqinhe roleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma AT ximingxu roleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma AT ximingxu roleofnoncodingrnasinthesorafenibresistanceofhepatocellularcarcinoma |